The integration of AI and digital tools in clinical trials raises significant ethical and regulatory challenges. At the OCT DACH 2024 conference, industry leaders discussed the need for a balance between innovation and patient safety. Regulatory bodies like the FDA are actively working on guidelines to address these concerns, but uncertainties remain.
Panelists emphasized the importance of ensuring that new technologies are accessible to all, particularly underrepresented communities. The conversation highlighted the necessity for clear regulatory boundaries as AI's role in clinical operations expands. Ultimately, the goal is to uplift the mission of clinical trials while maintaining equity and accessibility.
• Regulatory bodies are forming groups to address AI in clinical trials.
• Ethical concerns include patient safety, data privacy, and equitable access.
AI is being integrated into clinical trials to enhance operational efficiency and patient engagement.
Decentralized trials utilize digital health technologies to improve patient participation and data collection.
Digital health technologies encompass tools like AI and wearables that facilitate remote patient monitoring.
Neurimmune is a Swiss biotech company focused on developing innovative therapies, emphasizing the need for regulatory clarity in AI applications.
Pfizer is a global pharmaceutical company advocating for equitable access to innovations in clinical trials.
clinicaltrialsarena on MSN.com 11month
The American Journal of Managed Care 13month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.